even comp hiv get tough remdesivir
promis covid patient reason buy
gilead report product revenu y/i
sequenti beat consensu note revenu includ
earli refil patient weather covid storm
non-gaap ep note non-gaap ep longer regularli
exclud stock base compens beat consensu non-gaap
net incom flat y/i sequenti although note
neg impact one time charg mainli hcv-relat
inventori writedown gilead end year cash
growth come hiv franchis gilead flagship
top antiretrovir market continu
drive doubl digit y/i growth becom challeng much like saw
hcv franchis gilead may becom victim success
gilead late stage busi develop pipelin includ galapago
glpg nr partnership forti seven acquisit potenti
promis though timelin trial approv launch activ may
slow nonetheless still area look gilead potenti
return growth view cours also await
posit remdesivir remain promis
therapeut could potenti game changer pandem
howev unlik growth driver gilead remdesivir
approv seem like outcom revenu
could help partial off-set lost revenu due covid delay pipelin
sale approv drug maintain hold
commerci updat hcv revenu y/i
sequenti one contributor sequenti increas posit season effect
hcv continu look stabl predict posit hiv
franchis continu post y/i growth sale y/i though
sequenti season effect cite contributor import
note much earli purchas came hiv drug
make sens consid vulner popul biktarvi
remain regimen across patient group us eu though note
non-gilead hiv drug enter top prescrib regimen us
eu gilead still hold top us eu especi among
switch naiv patient could indic increas adopt competitor
though could also relat cannib franchis biktarvi
compani also work convert prep descovi prep patient
descovi vs truvada yescarta revenu sequenti
though expect impact bristol myer nr lawsuit april
result gilead owe damag royalti yescarta sale
substanti neg prospect gilead car-t franchis
impact manag comment guidanc although
compani discuss expect surround impact
busi activ base case predic peak march-juli potenti
return fall/wint lower impact phase return normal
recoveri underway though demand fundament remain strong
could neg impact due reduc visit healthcar provid
continu page
covid impact expect differ across franchis prep convers
descovi could particularli impact expect peak recov slowli
rest year impact alreadi seen increas earli refil
advanc order product larg hiv franchis increas revenu
enrol trial paus could lead delay develop timelin
busi expect return trajectori
filgotinib updat one promis avenu gilead futur growth inflammatori
pipelin includ potenti upcom launch filgotinib first step ra regulatori
submiss review us eu japan despit on-going pandem
gilead prepar launch possibl virtual launch need one issu
regulatori bodi may overwhelm focus therapeut
could delay approv data ulcer coliti still expect littl impact
complet enrol trial crohn diseas push back
data idiopath pulmonari fibrosi also expect
remdesivir gilead antivir drug remdesivir demonstr posit studi
far recent potenti rigor niaid studi
report posit data detail remdesivir may like first antivir
therapi approved/emerg author covid compani activ talk fda
discuss eua expect near futur larg respons
view rise gilead valuat year-to-d regulatori agenc
ema also begun review process author remdesivir
view drug remain repres promis treatment howev unlik
blockbust need justifi rise gilead market cap highlight
see remdesivir sovaldi-lik opportun gilead howev let review
data first
review previou bodi data length see note link
larg inconclus anecdot mix posit neg report niaid
data howev repres largest releas patient rigor
previou report sinc random placebo-control trial preliminari result
studi demonstr improv time recov day vs day
placebo improv surviv rate also note mortal rate
remdesivir vs placebo studi evalu daili infus day
though gilead data demonstr day dose produc significantli differ
commerci opportun far data look promis remdesivir could repres
import step address global pandem said also consid
invest perspect view commerci opportun remdesivir
though still potenti signific like limit number factor
suppli manufactur one constraint possibl commerci opportun
suppli remdesivir manag alreadi state believ prepar
addit cours treatment day treatment cycl octob
cours prove suffici data look like read way far would
doubl gilead also work expand manufactur side cooper partner
establish separ end-to-end manufactur suppli chain anoth way compani
work expand manufactur capac optim manufactur process
thu far reduc timelin month vs month
price access price access could work remdesivir commerci two
way access side remdesivir iv medic oral like tamiflu mean
go avail patient hospit nyc rate
confirm case howev could much lower base result
sero-survey suggest mani nyc resid could
diseas alreadi would suggest hospit rate side access
price ceo day alreadi state gilead ensur access issu
price high profil drug remdesivir midst pandem like
sovaldi-lik view may price humanitarian basi compani
alreadi donat individu dose
durat pandem durat pandem also play role
commerci opportun remdesivir may like depend speed
vaccin produc implement estim timelin vari wide
gener accept timelin month place vaccin earli
us govern also recent announc plan dub oper warp speed
target dose earli anoth consider could extend commerci
opportun remdesivir becom recurr flu-lik diseas howev
point pure specul
clinic util last factor consid competit remdesivir like
first antivir drug howev necessarili go effect
treatment develop includ antivir
antibodi treatment antibodi therapi may particularli use use
combin target multipl site viral protein reduc likelihood viru
develop resist alreadi seen antibodi cocktail emerg potenti cure
previous challeng diseas ebola regeneron nr
reduc mortal vs zmapp remdesivir nih/who
fund studi side howev remdesivir could posit baselin
therapi look combin
model updat adjust model reflect impact well
forti seven acquisit bristol myer car-t lawsuit settlement result
reduc revenu estim
respect reduc ep estim
respect
thousand except per share data
contract revenu
cog associ car-t
royalti merck us sale harvoni sovaldi
interest incom net
net loss attribut non control interest
net incom attribut gilead
basic ep attribut gilead sharehold
gaap dilut ep attribut gilead sharehold
compani report maxim group estim
